跳到正文
原文
MedPage Today·· 17 天前精选AI 评分65

TRANSFORM II:Magic Touch 西罗莫司药物涂层球囊在原生冠脉病变中不劣于药物洗脱支架

Study Strengthens Case for Stent-Free PCI in De Novo Coronary Lesions

AI 导读

TRANSFORM II 试验显示,原生冠脉病变行 PCI 的患者中,Magic Touch 西罗莫司药物涂层球囊 12 个月靶病变失败率为 2.1%,标准依维莫司药物洗脱支架为 2.4%(HR 0.86,95% CI 0.47-1.59),达到预设非劣效标准(P=0.004)。

推荐理由

TRANSFORM II 以 12 个月靶病变失败率为终点,为无植入 PCI 在原生冠脉病变中的可行性提供了随机对照数据。

正文 · 原文

— Magic Touch drug-coated balloon was noninferior to drug-eluting stent

by Nicole Lou, Senior Staff Writer, MedPage Today

November 2, 2026 • 5 min read

For de novo coronary lesions, drug-coated balloons (DCBs) were just as effective as standard drug-eluting stents, the TRANSFORM II trial showed.

Among patients with native coronary lesions undergoing percutaneous coronary intervention (PCI), the incidence of target lesion failure at 12 months -- including cardiac death, target vessel myocardial infarction (MI), and ischemia-driven target lesion revascularization -- was 2.1% with the Magic Touch sirolimus DCB and 2.4% with standard everolimus drug-eluting stents (DES; HR 0.86, 95% CI 0.47-1.59).

The DCB thus met prespecified criteria for noninferiority (P=0.004), reported Bernardo Cortese, MD, MSc, of Fondazione Ricerca e Innovazione Cardiovascolare in Milan, at the Transcatheter Cardiovascular Therapeutics annual conference hosted by the Cardiovascular Research Foundation.

"All of this put into the context of the available literature and the SELUTION De Novo clinical trial, I can conclude that the DCB approach is a safe and effective alternative to stents in a selected population of de novo lesions, but bear in mind that there is no class effect for drug-coated balloons," Cortese said.

The Magic Touch is a DCB designed to release sirolimus and have it stay in the arterial wall for 8 to 12 weeks. The appeal of a DCB is that, unlike DES, the standard of care for native coronary artery disease, no permanent metal is left behind during PCI.

DCBs are already established as a treatment for coronary in-stent restenosis, an indication for which paclitaxel- (the Agent DCB) and sirolimus-eluting DCB models (the Selution SLR) are available on the market. The evidence is more shaky for DCBs in native coronary artery disease, especially following the negative REC-CAGEFREE I trial, though in last year's SELUTION De Novo trial, the Selution DCB was shown to be noninferior to DES for rates of target lesion failure.

Of note, though rates of clinically driven target lesion revascularization were comparable between groups in TRANSFORM II, rates of any target lesion revascularization were higher in the DCB group (2.5% vs 1.1%, HR 2.31, 95% CI 1.10-4.85).

One theory, noted Cortese, is that physicians in this open-label trial may have tended to re-treat patients if they had subpar angiographic results after DCB therapy, whereas they may have been more conservative if they saw stents in the picture. "But the numbers were very low, so this is very, very speculative," he cautioned.

Besides the concern for target lesion revascularization, there is also the question of costs.

Session co-chair Ajay Kirtane, MD, of NewYork-Presbyterian/Columbia University Irving Medical Center in New York City, questioned if cath labs will be willing to switch to DCBs if the listing prices are about $6,000, compared with the $300 to $400 for DES.

"Financial reimbursements are still a big issue for centers, and I think it will continue to be, and particularly as we get farther along, and all the Medicare mandates end. So I think we'll have to wait and see," said panelist Jennifer Tremmel, MD, of Stanford University Medical Center in Palo Alto, California. "We're going to have to decide who gets DCB, who gets DES, when do they get it, and the financials are going to make a difference. So I'm curious to see how things go over the long term, and ultimately which patients we decide to use this in first."

TRANSFORM II was an open-label multicenter trial conducted in Europe, Asia, and Brazil. Participants had to have native coronary lesions with reference vessel diameters measuring 2.0 to 3.5 mm and lesion lengths no greater than 50 mm.

Following successful vessel preparation, patients were randomized 1:1 to the Magic Touch sirolimus DCB or the everolimus DES. Out of 2,699 people screened, 2,223 met criteria for entry, and 1,842 had successful lesion preparation and were ultimately randomized.

Mean age was about 63 years, and most patients were men. Initial presentation was roughly split between acute coronary syndrome and chronic coronary syndrome. Over 35% had diabetes, and about one in three had a prior MI. Approximately 30% had a high bleeding risk.

Lesions were type B2/C in about two in three cases. Bailout stenting was required in 7.6% of the DCB group.

Cortese reported that the minimum lumen diameter at baseline was about 0.92 mm, and in-device acute lumen gain averaged 0.76 mm with DCB and 1.30 mm with DES. On quantitative coronary angiography, the percent diameter stenosis at baseline was about 59%, and this dropped to 31% after lesion preparation. After PCI, the in-device percent diameter stenosis was 26.8% with DCB and 12.3% with DES. The proportion of patients with in-device residual stenosis <30% was 61.2% with DCB and 97.9% with DES.

Regarding the primary endpoint, intention-to-treat results were consistent with the per-protocol analysis, according to Cortese. Individual components of target lesion failure were also generally favorable with DCB:

  • Cardiac death: 0.4% vs 1.1% with DES
  • Target vessel MI: 1.0% vs 1.1%
  • Ischemia-driven target lesion revascularization: 0.9% vs 0.8%

A secondary endpoint, net adverse clinical events (all-cause mortality, any MI, ischemic stroke, or major bleeding), was not significantly different between the DCB and DES arms (4.1% vs 5.3%, HR 0.77, 95% CI 0.50-1.17).

Cortese stressed that these results do not apply to lesions with unsuccessful lesion preparation and excluded groups (patients with severe calcification, highly tortuous vessels, and left main or vein graft lesions; ST-segment elevation MI within 48 hours; previous PCI in the target vessel; complex bifurcation lesions; and ejection fractions below 30%, among others).

Among other study limitations, event rates were much lower than expected, and the results may have limited generalizability given that the operators were all from experienced DCB centers.

As for the question of whether DCBs might eventually reach superiority over DES for native coronary lesions, Cortese said this will require long-term data, and his group does plan to continue patient follow-up out to 5 years.

"We are expecting to see fewer events starting from year 3, like we have seen with paclitaxel-coated balloons in a patient-level meta-analysis," he said.

来源:MedPage Today · medpagetoday.com